Mineralys Restructures Drug Economics With $500 Million Financing
RADNOR, PA — Mineralys Therapeutics (NASDAQ: MLYS) has agreed to eliminate future royalty obligations tied to its lead drug candidate lorundrostat while securing access to up to $500 million in …
Mineralys Restructures Drug Economics With $500 Million Financing Read More